<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, viewport-fit=cover">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
<title>A Tale of Two Trials ‚Äî FXI Journal Club</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&family=Outfit:wght@300;400;500;600;700&family=JetBrains+Mono:wght@400;500;600&display=swap" rel="stylesheet">
<style>
:root {
  --bg:       #0a0e14;
  --bg2:      #111720;
  --bg3:      #182030;
  --border:   rgba(255,255,255,0.08);
  --amber:    #f0b429;
  --amber2:   #c88e10;
  --amber-bg: rgba(240,180,41,0.08);
  --red:      #ef4444;
  --red-bg:   rgba(239,68,68,0.08);
  --green:    #22c55e;
  --green-bg: rgba(34,197,94,0.08);
  --blue:     #60a5fa;
  --blue-bg:  rgba(96,165,250,0.08);
  --text:     #f0f4f8;
  --muted:    #8899aa;
  --dim:      #445566;
}

* { box-sizing: border-box; margin: 0; padding: 0; -webkit-tap-highlight-color: transparent; }

html, body {
  width: 100%; height: 100%;
  overflow: hidden;
  background: var(--bg);
  color: var(--text);
  font-family: 'Outfit', sans-serif;
  font-weight: 400;
  user-select: none;
  -webkit-user-select: none;
}

/* ‚îÄ‚îÄ DECK ‚îÄ‚îÄ */
#deck {
  position: fixed;
  inset: 0;
  overflow: hidden;
}

.slide {
  position: absolute;
  inset: 0;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding: 56px 72px;
  opacity: 0;
  pointer-events: none;
  transform: translateX(60px);
  transition: opacity 0.45s cubic-bezier(.4,0,.2,1), transform 0.45s cubic-bezier(.4,0,.2,1);
  overflow: hidden;
}
.slide.active {
  opacity: 1;
  pointer-events: all;
  transform: translateX(0);
}
.slide.exit-left {
  opacity: 0;
  transform: translateX(-60px);
  pointer-events: none;
}

/* ‚îÄ‚îÄ BACKGROUNDS ‚îÄ‚îÄ */
.slide::before {
  content: '';
  position: absolute;
  inset: 0;
  background: var(--bg);
  z-index: -2;
}
.bg-glow-amber::after {
  content: '';
  position: absolute;
  width: 700px; height: 700px;
  background: radial-gradient(circle, rgba(240,180,41,0.06) 0%, transparent 65%);
  top: -200px; right: -200px;
  z-index: -1;
  pointer-events: none;
}
.bg-glow-red::after {
  content: '';
  position: absolute;
  width: 700px; height: 700px;
  background: radial-gradient(circle, rgba(239,68,68,0.07) 0%, transparent 65%);
  bottom: -200px; left: -100px;
  z-index: -1;
  pointer-events: none;
}
.bg-glow-green::after {
  content: '';
  position: absolute;
  width: 700px; height: 700px;
  background: radial-gradient(circle, rgba(34,197,94,0.07) 0%, transparent 65%);
  bottom: -200px; right: -100px;
  z-index: -1;
  pointer-events: none;
}

/* ‚îÄ‚îÄ TYPOGRAPHY ‚îÄ‚îÄ */
.slide-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 12px;
  letter-spacing: 0.2em;
  text-transform: uppercase;
  color: var(--amber);
  margin-bottom: 18px;
  text-align: center;
}
.slide-label.red { color: var(--red); }
.slide-label.green { color: var(--green); }
.slide-label.blue { color: var(--blue); }
.slide-label.muted { color: var(--muted); }

h1 {
  font-family: 'Playfair Display', serif;
  font-size: clamp(36px, 5.5vw, 72px);
  font-weight: 600;
  line-height: 1.1;
  letter-spacing: -0.02em;
  text-align: center;
  color: var(--text);
}
h1 em { font-style: italic; color: var(--amber); }

h2 {
  font-family: 'Playfair Display', serif;
  font-size: clamp(28px, 4vw, 52px);
  font-weight: 600;
  line-height: 1.15;
  letter-spacing: -0.02em;
  color: var(--text);
  text-align: center;
}
h2 em { font-style: italic; color: var(--amber); }
h2.red em { color: var(--red); }
h2.green em { color: var(--green); }

h3 {
  font-family: 'Playfair Display', serif;
  font-size: clamp(22px, 3vw, 38px);
  font-weight: 400;
  font-style: italic;
  color: var(--muted);
  text-align: center;
  line-height: 1.3;
}

.body-text {
  font-size: clamp(16px, 2vw, 22px);
  color: var(--muted);
  text-align: center;
  line-height: 1.7;
  max-width: 820px;
  font-weight: 300;
}
.body-text strong { color: var(--text); font-weight: 600; }
.body-text em { color: var(--amber); font-style: normal; font-weight: 500; }
.body-text .red { color: var(--red); font-weight: 600; }
.body-text .green { color: var(--green); font-weight: 600; }

/* ‚îÄ‚îÄ SPACERS ‚îÄ‚îÄ */
.sp4  { height: 4px; }
.sp8  { height: 8px; }
.sp12 { height: 12px; }
.sp16 { height: 16px; }
.sp24 { height: 24px; }
.sp32 { height: 32px; }
.sp40 { height: 40px; }

/* ‚îÄ‚îÄ DIVIDER ‚îÄ‚îÄ */
.rule {
  width: 60px; height: 2px;
  background: var(--amber);
  margin: 24px auto;
  border-radius: 2px;
}
.rule.red { background: var(--red); }
.rule.green { background: var(--green); }

/* ‚îÄ‚îÄ CASE BOX ‚îÄ‚îÄ */
.case-box {
  background: var(--bg2);
  border: 1px solid var(--border);
  border-left: 3px solid var(--amber);
  border-radius: 0 12px 12px 0;
  padding: 28px 36px;
  max-width: 900px;
  width: 100%;
  text-align: left;
}
.case-box .case-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  letter-spacing: 0.2em;
  text-transform: uppercase;
  color: var(--amber);
  margin-bottom: 14px;
}
.case-box p {
  font-size: clamp(15px, 1.8vw, 20px);
  color: var(--text);
  line-height: 1.65;
  font-weight: 300;
}
.case-box p strong { color: var(--amber); font-weight: 600; }

/* ‚îÄ‚îÄ PROMPT LIST ‚îÄ‚îÄ */
.prompt-list {
  list-style: none;
  width: 100%;
  max-width: 860px;
  display: flex;
  flex-direction: column;
  gap: 14px;
  text-align: left;
}
.prompt-list li {
  background: var(--bg2);
  border: 1px solid var(--border);
  border-radius: 10px;
  padding: 16px 22px;
  font-size: clamp(14px, 1.6vw, 19px);
  color: var(--muted);
  line-height: 1.5;
  padding-left: 46px;
  position: relative;
}
.prompt-list li::before {
  content: '‚Üí';
  position: absolute;
  left: 18px;
  top: 16px;
  color: var(--amber);
  font-family: 'JetBrains Mono', monospace;
  font-size: 14px;
}
.prompt-list.red li::before { color: var(--red); content: '?'; }
.prompt-list.green li::before { color: var(--green); }

/* ‚îÄ‚îÄ COLUMNS ‚îÄ‚îÄ */
.cols {
  display: grid;
  gap: 16px;
  width: 100%;
  max-width: 1000px;
}
.cols-2 { grid-template-columns: 1fr 1fr; }
.cols-3 { grid-template-columns: 1fr 1fr 1fr; }

.card {
  background: var(--bg2);
  border: 1px solid var(--border);
  border-radius: 12px;
  padding: 22px 24px;
  text-align: left;
}
.card .card-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  letter-spacing: 0.18em;
  text-transform: uppercase;
  margin-bottom: 14px;
}
.card .card-label.amber { color: var(--amber); }
.card .card-label.red { color: var(--red); }
.card .card-label.green { color: var(--green); }
.card .card-label.blue { color: var(--blue); }
.card ul {
  list-style: none;
  display: flex;
  flex-direction: column;
  gap: 8px;
}
.card li {
  font-size: clamp(12px, 1.4vw, 16px);
  color: var(--muted);
  padding-left: 14px;
  position: relative;
  line-height: 1.5;
}
.card li::before { content: '‚Ä¢'; position: absolute; left: 0; }
.card.amber-border { border-color: rgba(240,180,41,0.25); }
.card.red-border { border-color: rgba(239,68,68,0.25); background: var(--red-bg); }
.card.green-border { border-color: rgba(34,197,94,0.25); background: var(--green-bg); }

/* ‚îÄ‚îÄ STAT BLOCKS ‚îÄ‚îÄ */
.stat-row {
  display: flex;
  gap: 24px;
  justify-content: center;
  flex-wrap: wrap;
}
.stat-block {
  background: var(--bg2);
  border: 1px solid var(--border);
  border-radius: 14px;
  padding: 24px 32px;
  text-align: center;
  min-width: 180px;
}
.stat-block .big {
  font-family: 'Playfair Display', serif;
  font-size: clamp(32px, 5vw, 60px);
  font-weight: 700;
  line-height: 1;
  color: var(--amber);
  margin-bottom: 8px;
}
.stat-block .big.red { color: var(--red); }
.stat-block .big.green { color: var(--green); }
.stat-block .small {
  font-size: clamp(11px, 1.3vw, 14px);
  color: var(--muted);
  line-height: 1.4;
  max-width: 150px;
}

/* ‚îÄ‚îÄ INSIGHT ‚îÄ‚îÄ */
.insight {
  background: var(--amber-bg);
  border: 1px solid rgba(240,180,41,0.2);
  border-radius: 12px;
  padding: 22px 30px;
  max-width: 860px;
  width: 100%;
  text-align: center;
  font-size: clamp(15px, 1.8vw, 21px);
  color: var(--text);
  line-height: 1.6;
  font-weight: 300;
}
.insight strong { color: var(--amber); font-weight: 600; }
.insight.red { background: var(--red-bg); border-color: rgba(239,68,68,0.2); }
.insight.red strong { color: var(--red); }
.insight.green { background: var(--green-bg); border-color: rgba(34,197,94,0.2); }
.insight.green strong { color: var(--green); }

/* ‚îÄ‚îÄ BADGE ‚îÄ‚îÄ */
.badge {
  display: inline-block;
  font-family: 'JetBrains Mono', monospace;
  font-size: 12px;
  padding: 5px 14px;
  border-radius: 20px;
  font-weight: 600;
  letter-spacing: 0.05em;
}
.badge.amber { background: var(--amber-bg); color: var(--amber); border: 1px solid rgba(240,180,41,0.3); }
.badge.red { background: var(--red-bg); color: var(--red); border: 1px solid rgba(239,68,68,0.3); }
.badge.green { background: var(--green-bg); color: var(--green); border: 1px solid rgba(34,197,94,0.3); }
.badge.blue { background: var(--blue-bg); color: var(--blue); border: 1px solid rgba(96,165,250,0.3); }

/* ‚îÄ‚îÄ VERSUS ‚îÄ‚îÄ */
.versus {
  display: grid;
  grid-template-columns: 1fr auto 1fr;
  gap: 20px;
  align-items: center;
  width: 100%;
  max-width: 920px;
}
.versus-divider {
  font-family: 'Playfair Display', serif;
  font-size: 28px;
  font-style: italic;
  color: var(--dim);
  text-align: center;
}

/* ‚îÄ‚îÄ PHYSIO TABLE ‚îÄ‚îÄ */
.physio-split {
  display: grid;
  grid-template-columns: 1fr 1fr;
  gap: 20px;
  width: 100%;
  max-width: 900px;
}
.physio-col {
  border-radius: 12px;
  padding: 22px 26px;
  text-align: left;
}
.physio-col.hem {
  background: var(--green-bg);
  border: 1px solid rgba(34,197,94,0.2);
}
.physio-col.throm {
  background: var(--red-bg);
  border: 1px solid rgba(239,68,68,0.2);
}
.physio-col .phys-title {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  text-transform: uppercase;
  letter-spacing: 0.18em;
  margin-bottom: 16px;
  font-weight: 600;
}
.physio-col.hem .phys-title { color: var(--green); }
.physio-col.throm .phys-title { color: var(--red); }
.physio-col ul { list-style: none; display: flex; flex-direction: column; gap: 10px; }
.physio-col li {
  font-size: clamp(12px, 1.5vw, 16px);
  color: var(--muted);
  padding-left: 16px;
  position: relative;
  line-height: 1.5;
}
.physio-col.hem li::before { content: '‚úì'; position: absolute; left: 0; color: var(--green); font-weight: 700; font-size: 12px; top: 1px; }
.physio-col.throm li::before { content: '‚Üì'; position: absolute; left: 0; color: var(--red); font-weight: 700; font-size: 12px; top: 1px; }

/* ‚îÄ‚îÄ ACT MARKER ‚îÄ‚îÄ */
.act-marker {
  display: flex;
  align-items: center;
  gap: 16px;
  margin-bottom: 8px;
}
.act-line {
  flex: 1;
  height: 1px;
  background: var(--border);
}
.act-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  letter-spacing: 0.2em;
  text-transform: uppercase;
  color: var(--dim);
}

/* ‚îÄ‚îÄ OBJECTIVES LIST ‚îÄ‚îÄ */
.obj-list {
  list-style: none;
  display: flex;
  flex-direction: column;
  gap: 12px;
  width: 100%;
  max-width: 840px;
  text-align: left;
}
.obj-list li {
  display: flex;
  gap: 16px;
  align-items: flex-start;
  background: var(--bg2);
  border: 1px solid var(--border);
  border-radius: 10px;
  padding: 14px 20px;
  font-size: clamp(13px, 1.5vw, 17px);
  color: var(--muted);
  line-height: 1.5;
}
.obj-list .num {
  font-family: 'JetBrains Mono', monospace;
  font-size: 12px;
  color: var(--amber);
  background: var(--amber-bg);
  min-width: 24px;
  height: 24px;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  flex-shrink: 0;
  font-weight: 600;
  margin-top: 1px;
}

/* ‚îÄ‚îÄ REVERSAL ALERT ‚îÄ‚îÄ */
.reversal-alert {
  background: rgba(239,68,68,0.07);
  border: 2px solid rgba(239,68,68,0.35);
  border-radius: 14px;
  padding: 28px 36px;
  max-width: 920px;
  width: 100%;
  text-align: left;
}
.reversal-alert .alert-title {
  font-family: 'JetBrains Mono', monospace;
  font-size: 12px;
  letter-spacing: 0.2em;
  text-transform: uppercase;
  color: var(--red);
  margin-bottom: 16px;
}
.reversal-alert ul {
  list-style: none;
  display: grid;
  grid-template-columns: 1fr 1fr;
  gap: 10px;
}
.reversal-alert li {
  font-size: clamp(12px, 1.5vw, 16px);
  color: #fca5a5;
  padding-left: 20px;
  position: relative;
  line-height: 1.5;
}
.reversal-alert li::before { content: '‚úó'; position: absolute; left: 0; color: var(--red); font-weight: 700; }

/* ‚îÄ‚îÄ DEBATE ‚îÄ‚îÄ */
.debate-split {
  display: grid;
  grid-template-columns: 1fr 1fr;
  gap: 0;
  width: 100%;
  max-width: 960px;
  border: 1px solid var(--border);
  border-radius: 14px;
  overflow: hidden;
}
.debate-col {
  padding: 24px 28px;
  text-align: left;
}
.debate-col.pro { background: var(--green-bg); border-right: 1px solid var(--border); }
.debate-col.con { background: var(--red-bg); }
.debate-col .dtitle {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  letter-spacing: 0.2em;
  text-transform: uppercase;
  margin-bottom: 16px;
  font-weight: 600;
}
.debate-col.pro .dtitle { color: var(--green); }
.debate-col.con .dtitle { color: var(--red); }
.debate-col ul { list-style: none; display: flex; flex-direction: column; gap: 10px; }
.debate-col li {
  font-size: clamp(12px, 1.4vw, 16px);
  color: var(--muted);
  padding-left: 18px;
  position: relative;
  line-height: 1.5;
}
.debate-col.pro li::before { content: '+'; position: absolute; left: 0; color: var(--green); font-weight: 800; }
.debate-col.con li::before { content: '‚àí'; position: absolute; left: 0; color: var(--red); font-weight: 800; }

/* ‚îÄ‚îÄ TAKEAWAYS ‚îÄ‚îÄ */
.takeaway-grid {
  display: grid;
  grid-template-columns: 1fr 1fr 1fr;
  gap: 12px;
  width: 100%;
  max-width: 1020px;
  text-align: left;
}
.takeaway-item {
  background: var(--bg2);
  border: 1px solid var(--border);
  border-radius: 10px;
  padding: 16px 18px;
  display: flex;
  gap: 12px;
  align-items: flex-start;
}
.takeaway-n {
  font-family: 'JetBrains Mono', monospace;
  font-size: 13px;
  color: var(--amber);
  font-weight: 600;
  flex-shrink: 0;
  margin-top: 1px;
}
.takeaway-t {
  font-size: clamp(11px, 1.3vw, 14px);
  color: var(--muted);
  line-height: 1.5;
}
.takeaway-t strong { color: var(--text); font-weight: 600; }

/* ‚îÄ‚îÄ AGENDA BAR ‚îÄ‚îÄ */
.agenda-track {
  display: flex;
  gap: 3px;
  width: 100%;
  max-width: 800px;
  height: 10px;
  border-radius: 5px;
  overflow: hidden;
}
.ag-seg {
  border-radius: 2px;
  opacity: 0.6;
}
.agenda-labels {
  display: flex;
  gap: 16px;
  flex-wrap: wrap;
  justify-content: center;
  margin-top: 12px;
}
.ag-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  color: var(--muted);
  display: flex;
  align-items: center;
  gap: 6px;
}
.ag-dot { width: 8px; height: 8px; border-radius: 50%; }

/* ‚îÄ‚îÄ DRUG TABLE ‚îÄ‚îÄ */
.drug-table {
  width: 100%;
  max-width: 960px;
  border-collapse: collapse;
  font-size: clamp(11px, 1.3vw, 15px);
}
.drug-table th {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  color: var(--dim);
  padding: 10px 14px;
  background: var(--bg3);
  border-bottom: 1px solid var(--border);
  text-align: left;
}
.drug-table td {
  padding: 12px 14px;
  border-bottom: 1px solid var(--border);
  color: var(--muted);
  vertical-align: top;
  line-height: 1.5;
}
.drug-table tr:last-child td { border-bottom: none; }
.drug-table tr:nth-child(even) td { background: rgba(255,255,255,0.02); }
.drug-table .dn { font-weight: 600; color: var(--text); font-size: 1.05em; }
.drug-table .dc { font-size: 0.85em; color: var(--dim); }

/* ‚îÄ‚îÄ PROGRESS BAR ‚îÄ‚îÄ */
#progress-bar {
  position: fixed;
  bottom: 0; left: 0;
  height: 3px;
  background: var(--amber);
  transition: width 0.4s cubic-bezier(.4,0,.2,1);
  z-index: 100;
  border-radius: 0 2px 0 0;
}

/* ‚îÄ‚îÄ SLIDE COUNTER ‚îÄ‚îÄ */
#slide-counter {
  position: fixed;
  bottom: 16px;
  right: 20px;
  font-family: 'JetBrains Mono', monospace;
  font-size: 12px;
  color: var(--dim);
  z-index: 100;
  pointer-events: none;
}
#slide-counter span { color: var(--muted); }

/* ‚îÄ‚îÄ NAV TOUCH ZONES ‚îÄ‚îÄ */
.nav-zone {
  position: fixed;
  top: 0;
  width: 15%;
  height: 100%;
  z-index: 50;
  cursor: pointer;
  display: flex;
  align-items: center;
  justify-content: center;
  opacity: 0;
  transition: opacity 0.2s;
}
.nav-zone:hover, .nav-zone:active { opacity: 1; }
#nav-prev { left: 0; }
#nav-next { right: 0; }
.nav-arrow {
  width: 36px; height: 36px;
  background: rgba(255,255,255,0.06);
  border: 1px solid var(--border);
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  color: var(--muted);
  font-size: 16px;
}

/* ‚îÄ‚îÄ FULLSCREEN BTN ‚îÄ‚îÄ */
#fullscreen-btn {
  position: fixed;
  top: 16px;
  right: 18px;
  z-index: 100;
  background: rgba(255,255,255,0.05);
  border: 1px solid var(--border);
  border-radius: 8px;
  padding: 7px 12px;
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  color: var(--dim);
  cursor: pointer;
  transition: color 0.2s, background 0.2s;
}
#fullscreen-btn:hover { color: var(--muted); background: rgba(255,255,255,0.08); }

/* ‚îÄ‚îÄ SECTION PILL ‚îÄ‚îÄ */
.section-pill {
  position: fixed;
  top: 16px;
  left: 20px;
  z-index: 100;
  font-family: 'JetBrains Mono', monospace;
  font-size: 11px;
  color: var(--dim);
  letter-spacing: 0.1em;
  pointer-events: none;
}

/* ‚îÄ‚îÄ MONO TEXT ‚îÄ‚îÄ */
.mono { font-family: 'JetBrains Mono', monospace; }

/* ‚îÄ‚îÄ TITLE SLIDE ‚îÄ‚îÄ */
.title-rule {
  width: 100%;
  max-width: 600px;
  height: 1px;
  background: linear-gradient(to right, transparent, var(--amber), transparent);
  margin: 28px auto;
}

.meta-row {
  display: flex;
  gap: 40px;
  justify-content: center;
  flex-wrap: wrap;
  margin-top: 8px;
}
.meta-item { text-align: center; }
.meta-label {
  font-family: 'JetBrains Mono', monospace;
  font-size: 10px;
  text-transform: uppercase;
  letter-spacing: 0.15em;
  color: var(--dim);
  margin-bottom: 4px;
}
.meta-val {
  font-size: clamp(12px, 1.4vw, 15px);
  color: var(--muted);
}

/* iPad safe areas */
@supports (padding-top: env(safe-area-inset-top)) {
  .slide {
    padding-top: calc(56px + env(safe-area-inset-top));
    padding-bottom: calc(48px + env(safe-area-inset-bottom));
    padding-left: calc(72px + env(safe-area-inset-left));
    padding-right: calc(72px + env(safe-area-inset-right));
  }
}
</style>
</head>
<body>

<div id="deck">

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 01: TITLE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-amber active" data-section="Introduction">
    <div class="slide-label">Internal Medicine Journal Club ¬∑ 45 Minutes</div>
    <div class="sp8"></div>
    <h1>A Tale of<br><em>Two Trials</em></h1>
    <div class="title-rule"></div>
    <h3>Factor XI Inhibitors ‚Äî One Drug Class, Opposite Outcomes</h3>
    <div class="sp16"></div>
    <div class="insight" style="font-size:clamp(15px,1.8vw,22px); max-width:700px; padding:22px 36px; font-style:italic; margin:0 auto;">
      &ldquo;It was the best of times, it was the worst of times.&rdquo;
    </div>
    <div class="sp24"></div>
    <div class="meta-row">
      <div class="meta-item"><div class="meta-label">Pre-reading</div><div class="meta-val">AZALEA-TIMI 71 ¬∑ NEJM 2025</div></div>
      <div class="meta-item"><div class="meta-label">Also assign</div><div class="meta-val">OCEANIC-AF ¬∑ NEJM 2024</div></div>
      <div class="meta-item"><div class="meta-label">Duration</div><div class="meta-val">45 minutes</div></div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 02: AGENDA ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Agenda">
    <div class="slide-label">Session Overview</div>
    <h2>45 Minutes, One Narrative Arc</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <div class="agenda-track">
      <div class="ag-seg" style="flex:5; background:var(--amber);"></div>
      <div class="ag-seg" style="flex:4; background:#7c6bd0;"></div>
      <div class="ag-seg" style="flex:8; background:#5e7ab8;"></div>
      <div class="ag-seg" style="flex:5; background:#4a9ead;"></div>
      <div class="ag-seg" style="flex:14; background:var(--amber2);"></div>
      <div class="ag-seg" style="flex:5; background:var(--red);"></div>
      <div class="ag-seg" style="flex:5; background:var(--green);"></div>
      <div class="ag-seg" style="flex:3; background:var(--dim);"></div>
    </div>
    <div class="agenda-labels">
      <div class="ag-label"><div class="ag-dot" style="background:var(--amber);"></div>Case (5m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:#7c6bd0;"></div>Context (4m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:#5e7ab8;"></div>Physiology (8m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:#4a9ead;"></div>Drugs (5m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:var(--amber2);"></div>Trials (14m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:var(--red);"></div>Reversal (5m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:var(--green);"></div>Inpatient (5m)</div>
      <div class="ag-label"><div class="ag-dot" style="background:var(--dim);"></div>Close (4m)</div>
    </div>
    <div class="sp32"></div>
    <div class="insight" style="font-size: clamp(14px,1.6vw,19px);">
      The structure follows a <strong>four-act trial narrative</strong> ‚Äî Phase 2 excitement ‚Üí OCEANIC-AF failure (Phase 3) ‚Üí AZALEA-TIMI 71 signal (Phase 2b) ‚Üí LILAC-TIMI 76 as the unanswered question (Phase 3, ongoing). Understanding <em>why</em> one drug failed and one succeeded is the core lesson.
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 03: OBJECTIVES ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Objectives">
    <div class="slide-label">Learning Objectives</div>
    <h2>By the End of This Session</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <ul class="obj-list">
      <li><div class="num">1</div>Explain why FXI is mechanistically distinct from FXa/thrombin as an anticoagulation target</li>
      <li><div class="num">2</div>Distinguish <strong>FXI inhibition</strong> from <strong>FXIa inhibition</strong> ‚Äî and why this difference predicted trial outcomes</li>
      <li><div class="num">3</div>Critically appraise AZALEA-TIMI 71 and OCEANIC-AF: design, endpoints, early stopping, phase distinctions, and what LILAC-TIMI 76 must still prove</li>
      <li><div class="num">4</div>Articulate the class-wide absence of reversal agents and its inpatient implications</li>
      <li><div class="num">5</div>Identify the highest-priority patient populations for FXI inhibitor candidacy</li>
    </ul>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 04: OPENING CASE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-amber" data-section="Case">
    <div class="slide-label">Opening Case ‚Äî Keep This Patient in Mind</div>
    <div class="sp12"></div>
    <div class="case-box">
      <div class="case-label">Inpatient Scenario</div>
      <p>
        A <strong>78-year-old woman</strong> with <strong>paroxysmal AF</strong> (CHA‚ÇÇDS‚ÇÇ-VASc 5),
        <strong>ESRD on hemodialysis</strong>, and a <strong>hospitalization 4 months ago
        for a GI bleed from a cecal AVM</strong> is admitted with aspiration pneumonia.
        Her apixaban was held at that admission. Hematology recommended indefinite hold.
        Cardiology now requests a formal anticoagulation recommendation.
      </p>
    </div>
    <div class="sp24"></div>
    <ul class="prompt-list">
      <li>Who would anticoagulate this patient <em>today?</em> Show of hands.</li>
      <li>What single factor is most driving your decision ‚Äî the stroke risk, the bleed history, or the renal function?</li>
      <li>Would your answer change if the GI bleed was <em>12 months ago</em> instead of 4?</li>
    </ul>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 05: CASE PIVOT ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-amber" data-section="Case">
    <div class="insight" style="font-size: clamp(17px, 2.2vw, 28px); padding: 36px 48px; max-width: 780px;">
      An estimated <strong>3‚Äì4 million Americans</strong> meet guideline criteria for anticoagulation in AF but are deemed ineligible due to bleeding risk.<br><br>
      This patient is not an edge case. She is the <em>target population</em>.<br><br>
      <strong>What if a drug could change the threshold?</strong>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 06: WHY DOACs FAIL ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Context">
    <div class="slide-label muted">Why Current Anticoagulation Is Incomplete</div>
    <h2>DOACs Solved Half the Problem</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <div class="cols cols-2" style="max-width:880px;">
      <div class="card amber-border">
        <div class="card-label amber">What DOACs Achieved</div>
        <ul>
          <li>~50% ICH reduction vs. warfarin</li>
          <li>No INR monitoring required</li>
          <li>Predictable pharmacokinetics</li>
          <li>Reversal agents now available (FXa, IIa)</li>
        </ul>
      </div>
      <div class="card red-border">
        <div class="card-label red">What DOACs Couldn't Solve</div>
        <ul>
          <li>Major bleeding: ~2‚Äì4%/year in AF trials</li>
          <li>GI bleeding elevated vs. warfarin (dabigatran, rivaroxaban, edoxaban)</li>
          <li>ICH ~0.5‚Äì0.8%/year ‚Äî reduced but not eliminated</li>
          <li>No safe option for prior ICH, active GI disease, or ESRD</li>
        </ul>
      </div>
    </div>
    <div class="sp24"></div>
    <div class="insight">
      The problem is not drug-specific ‚Äî it is <strong>mechanistic</strong>. Both FXa and thrombin are required for normal hemostasis. Blocking them reduces thrombosis but necessarily impairs the physiologic response to injury.
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 07: THE FUNDAMENTAL QUESTION ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Context">
    <div class="insight" style="font-size: clamp(18px, 2.3vw, 30px); padding: 44px 52px; max-width: 820px;">
      Is there a node in the coagulation cascade that contributes predominantly to <strong>pathologic thrombosis</strong> but is dispensable for <strong>normal hemostatic plug formation?</strong>
    </div>
    <div class="sp32"></div>
    <h3>This question launched the FXI inhibitor program.</h3>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 08: CASCADE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Physiology">
    <div class="slide-label">Coagulation Physiology</div>
    <h2>FXI's Role in the Cascade</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <div class="cols cols-2" style="max-width: 900px; gap: 32px;">
      <div>
        <div class="card-label green" style="font-family:'JetBrains Mono',monospace; font-size:10px; letter-spacing:0.18em; text-transform:uppercase; margin-bottom:14px; display:block;">Extrinsic (TF) Pathway ‚Äî Primary Hemostasis</div>
        <div style="display:flex; flex-direction:column; gap:8px;">
          <div class="card" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--muted);">Tissue Factor + FVIIa<div style="font-size:0.85em; color:var(--dim); margin-top:2px;">Vascular injury ‚Üí immediate activation</div></div>
          <div style="text-align:center; color:var(--green); font-size:18px;">‚Üì</div>
          <div class="card" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--muted);">FXa + FVa ‚Üí Thrombin (FIIa)<div style="font-size:0.85em; color:var(--dim); margin-top:2px;">Targeted by DOACs</div></div>
          <div style="text-align:center; color:var(--green); font-size:18px;">‚Üì</div>
          <div class="card green-border" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--text);">Fibrin Clot ‚Äî Primary Hemostatic Plug</div>
        </div>
      </div>
      <div>
        <div class="card-label amber" style="font-family:'JetBrains Mono',monospace; font-size:10px; letter-spacing:0.18em; text-transform:uppercase; margin-bottom:14px; display:block;">Intrinsic (Contact) Pathway ‚Äî Thrombosis Amplifier</div>
        <div style="display:flex; flex-direction:column; gap:8px;">
          <div class="card" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--muted);">FXII ‚Üí FXIIa<div style="font-size:0.85em; color:var(--dim); margin-top:2px;">Contact activation ‚Äî stasis, polyanions, foreign surfaces</div></div>
          <div style="text-align:center; color:var(--amber); font-size:18px;">‚Üì</div>
          <div class="card amber-border" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--amber); font-weight:600;">FXI ‚Üí FXIa ‚Üê DRUG TARGET<div style="font-size:0.85em; color:var(--muted); margin-top:2px; font-weight:400;">Amplification of thrombus propagation</div></div>
          <div style="text-align:center; color:var(--amber); font-size:18px;">‚Üì üéØ</div>
          <div class="card" style="padding:12px 16px; font-size:clamp(12px,1.4vw,15px); color:var(--muted);">FIXa + FVIIIa ‚Üí FXa ‚Üí Common pathway</div>
        </div>
      </div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 09: HEMOPHILIA C ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Physiology">
    <div class="slide-label">The Natural Human Experiment</div>
    <h2>Congenital FXI Deficiency<br><em>(Hemophilia C)</em></h2>
    <div class="rule"></div>
    <div class="sp12"></div>
    <div class="physio-split">
      <div class="physio-col hem">
        <div class="phys-title">Effect on Hemostasis</div>
        <ul>
          <li>No spontaneous bleeding</li>
          <li>Normal wound healing</li>
          <li>Bleeding only with surgery/trauma ‚Äî and only at high-fibrinolytic sites (dental, urologic, nasal)</li>
          <li>Contrast with hemophilia A/B: spontaneous hemarthroses, life-threatening bleeds</li>
          <li>Variable phenotype even among homozygotes</li>
        </ul>
      </div>
      <div class="physio-col throm">
        <div class="phys-title">Effect on Thrombosis</div>
        <ul>
          <li>Significantly reduced DVT and PE rates</li>
          <li>Lower ischemic stroke risk ‚Äî especially cardioembolic</li>
          <li>Reduced prevalence of AF-related thrombus</li>
          <li>Supported by Israeli population registry data (Salomon et al., Blood 2008)</li>
          <li>Effect most pronounced in venous and cardioembolic (stasis-driven) events</li>
        </ul>
      </div>
    </div>
    <div class="sp16"></div>
    <div class="insight">
      Autosomal recessive ¬∑ Common in Ashkenazi Jewish populations (~0.3%) ¬∑ This population data is the entire pharmacological justification for the drug class
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 10: KEY INSIGHT ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Physiology">
    <div class="insight" style="font-size: clamp(16px, 2vw, 24px); padding: 40px 52px; max-width: 840px;">
      <strong>FXI inhibition can uncouple thrombosis from hemostasis</strong> ‚Äî reducing clot propagation in pathologic contexts driven by stasis and contact activation, while preserving the extrinsic-pathway-driven primary hemostatic response to injury.<br><br>
      This would be a <em>fundamentally different risk profile</em> from any current anticoagulant.
    </div>
    <div class="sp32"></div>
    <ul class="prompt-list" style="max-width: 700px;">
      <li>Why doesn't hemophilia C cause spontaneous bleeding like hemophilia A?</li>
      <li>What types of thrombosis do you predict FXI inhibitors work best for ‚Äî arterial, venous, cardioembolic?</li>
    </ul>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 11: FXI vs FXIa ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Drug Classes">
    <div class="slide-label">Critical Mechanistic Distinction</div>
    <h2>FXI Inhibition vs.<br><em>FXIa</em> Inhibition</h2>
    <div class="rule"></div>
    <div class="sp12"></div>
    <div class="versus">
      <div class="card green-border" style="padding: 24px 28px; text-align:left;">
        <div class="card-label green" style="font-family:'JetBrains Mono',monospace; font-size:11px; letter-spacing:0.15em; text-transform:uppercase; margin-bottom:14px; display:block;">FXI Inhibition (Upstream)</div>
        <p style="font-size:clamp(13px,1.5vw,17px); color:var(--muted); line-height:1.6;">Targets the <strong style="color:var(--text);">zymogen before activation</strong>. Prevents FXI ‚Üí FXIa conversion entirely. Complete upstream blockade of the amplification loop.<br><br><em style="color:var(--green);">Example: Abelacimab (monoclonal antibody)</em></p>
      </div>
      <div class="versus-divider">vs.</div>
      <div class="card red-border" style="padding: 24px 28px; text-align:left;">
        <div class="card-label red" style="font-family:'JetBrains Mono',monospace; font-size:11px; letter-spacing:0.15em; text-transform:uppercase; margin-bottom:14px; display:block;">FXIa Inhibition (Downstream)</div>
        <p style="font-size:clamp(13px,1.5vw,17px); color:var(--muted); line-height:1.6;">Competes at the <strong style="color:var(--text);">active site of the already-activated enzyme</strong>. Leaves unactivated FXI available. Partial suppression depending on dose and kinetics.<br><br><em style="color:var(--red);">Examples: Asundexian, Milvexian (small molecules)</em></p>
      </div>
    </div>
    <div class="sp20"></div>
    <div class="insight red" style="font-size:clamp(13px,1.6vw,18px);">
      <strong>This distinction appears to have determined which drug class succeeded in Phase 3 and which failed.</strong> Keep it in mind as we walk through the trials.
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 12: DRUG TABLE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Drug Classes">
    <div class="slide-label">Agents in Development</div>
    <h2>The FXI Inhibitor Landscape</h2>
    <div class="rule"></div>
    <div class="sp12"></div>
    <table class="drug-table">
      <thead>
        <tr>
          <th>Agent</th>
          <th>Class / Target</th>
          <th>Dosing</th>
          <th>Key AF Trial</th>
          <th>Status</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td><span class="dn">Abelacimab</span><span class="dc">Sanofi / TIMI</span></td>
          <td>mAb ‚Üí FXI zymogen (upstream)</td>
          <td>SC monthly ¬∑ No renal clearance ¬∑ t¬Ω ~30 days</td>
          <td>AZALEA-TIMI 71 (Ph2b complete) ¬∑ LILAC-TIMI 76 (Ph3 ongoing)</td>
          <td><span class="badge green">Phase 3 ‚úì</span></td>
        </tr>
        <tr>
          <td><span class="dn">Asundexian</span><span class="dc">Bayer</span></td>
          <td>Small molecule ‚Üí FXIa active site</td>
          <td>PO QD ¬∑ ~60% renal ¬∑ t¬Ω ~20h</td>
          <td>OCEANIC-AF</td>
          <td><span class="badge red">Stopped ‚Äî Inferior</span></td>
        </tr>
        <tr>
          <td><span class="dn">Milvexian</span><span class="dc">BMS / J&amp;J</span></td>
          <td>Small molecule ‚Üí FXIa active site</td>
          <td>PO BID ¬∑ Hepatic/renal ¬∑ t¬Ω ~12h</td>
          <td>LIBREXIA-AF (ongoing)</td>
          <td><span class="badge blue">Phase 3 ongoing</span></td>
        </tr>
        <tr>
          <td><span class="dn">Fesomersen</span><span class="dc">Ionis / AZ</span></td>
          <td>ASO ‚Üí Reduces hepatic FXI synthesis</td>
          <td>SC biweekly ‚Üí monthly ¬∑ Very long offset (weeks‚Äìmonths)</td>
          <td>No AF trial yet</td>
          <td><span class="badge amber">Phase 2 complete</span></td>
        </tr>
      </tbody>
    </table>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 13: ACT I ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Trials">
    <div class="slide-label">Trial Narrative</div>
    <div class="act-marker" style="width:100%; max-width:700px;">
      <div class="act-line"></div>
      <div class="act-label">Act I ¬∑ Phase 2 Promise</div>
      <div class="act-line"></div>
    </div>
    <div class="sp16"></div>
    <h2>The Excitement Builds</h2>
    <div class="rule"></div>
    <div class="sp12"></div>
    <div class="cols cols-2" style="max-width:880px;">
      <div class="card amber-border">
        <div class="card-label amber">What Phase 2 Showed</div>
        <ul>
          <li>FXI/FXIa inhibition consistently reduced VTE in orthopedic prophylaxis vs. LMWH</li>
          <li><strong>PACIFIC-AF</strong>: asundexian 50mg reduced bleeding vs. apixaban with efficacy signal intact</li>
          <li>Consistent ICH reduction signal across agents</li>
          <li>Phase 2 excitement was real ‚Äî and warranted investigation</li>
        </ul>
      </div>
      <div class="card red-border">
        <div class="card-label red">The Cautionary Flags Missed</div>
        <ul>
          <li>VTE prophylaxis trials used <strong>asymptomatic venographic DVT</strong> as primary endpoint ‚Äî a surrogate with poor track record</li>
          <li>Phase 2 AF studies not powered for clinical stroke outcomes</li>
          <li>Dose-finding for adequate FXIa suppression in stroke prevention was not validated</li>
          <li>History lesson: ximelagatran had Phase 2 promise too</li>
        </ul>
      </div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 14: OCEANIC-AF DESIGN ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-red" data-section="Trials">
    <div class="slide-label red">Act II ¬∑ The Reality Check</div>
    <div class="act-marker" style="width:100%; max-width:700px;">
      <div class="act-line" style="background: rgba(239,68,68,0.3);"></div>
      <div class="act-label" style="color:var(--red);">OCEANIC-AF</div>
      <div class="act-line" style="background: rgba(239,68,68,0.3);"></div>
    </div>
    <div class="sp8"></div>
    <h2 class="red"><em>Asundexian</em> vs. Apixaban in AF</h2>
    <div class="rule red"></div>
    <div class="sp12"></div>
    <div class="cols cols-2" style="max-width:860px;">
      <div class="card">
        <div class="card-label red">Trial Design</div>
        <ul>
          <li>Double-blind, double-dummy, active-controlled</li>
          <li><strong>Noninferiority design</strong> vs. apixaban</li>
          <li>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•2 (men) / ‚â•3 (women)</li>
          <li>~14,000 patients ¬∑ 41 countries</li>
          <li>Primary efficacy: stroke or systemic embolism</li>
          <li>Primary safety: major bleeding (ISTH)</li>
        </ul>
      </div>
      <div class="card red-border">
        <div class="card-label red">The Result</div>
        <ul>
          <li>Stopped early by DSMB at interim analysis</li>
          <li>Asundexian <strong style="color:var(--red);">FAILED noninferiority</strong> for stroke/SE prevention</li>
          <li>HR for stroke &gt;1.0, upper CI exceeds pre-specified margin</li>
          <li>Major bleeding <span style="color:var(--green);">significantly lower</span> with asundexian ‚úì</li>
          <li>Safety benefit could not offset efficacy failure</li>
        </ul>
      </div>
    </div>
    <div class="sp16"></div>
    <div class="insight red">Bayer / NEJM‚ÄìCirculation 2024 ¬∑ Presented ESC 2024</div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 15: OCEANIC CRITIQUE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-red" data-section="Trials">
    <div class="slide-label red">Critical Appraisal ‚Äî OCEANIC-AF</div>
    <h2>What Should We Take From This?</h2>
    <div class="rule red"></div>
    <div class="sp16"></div>
    <ul class="prompt-list red">
      <li>Noninferiority design: is it possible asundexian was designed to demonstrate safety <em>while assuming</em> efficacy would hold? Was it set up to fail?</li>
      <li>The trial was stopped for <strong>inferiority</strong> ‚Äî not futility, not safety. How does this differ from trials stopped for benefit, and how should it affect interpretation?</li>
      <li>Asundexian targets FXIa (active enzyme only). Could inadequate suppression of the FXI amplification loop explain the stroke signal? What dose would you test next?</li>
      <li>Bleeding <em>was</em> reduced. Does this argue for dose optimization, or does it confirm FXIa inhibition is the wrong target for stroke prevention entirely?</li>
    </ul>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 16: AZALEA DESIGN ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-green" data-section="Trials">
    <div class="slide-label green">Act III ¬∑ The Signal</div>
    <div class="act-marker" style="width:100%; max-width:700px;">
      <div class="act-line" style="background: rgba(34,197,94,0.3);"></div>
      <div class="act-label" style="color:var(--green);">AZALEA-TIMI 71 ¬∑ Phase 2b</div>
      <div class="act-line" style="background: rgba(34,197,94,0.3);"></div>
    </div>
    <div class="sp8"></div>
    <h2 class="green"><em>Abelacimab</em> vs. Rivaroxaban in AF</h2>
    <div class="rule green"></div>
    <div class="sp12"></div>
    <div class="cols cols-2" style="max-width:880px;">
      <div class="card">
        <div class="card-label green">Trial Design</div>
        <ul>
          <li>Phase 2b ¬∑ Randomized, open-label, <strong>blinded adjudication</strong></li>
          <li>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•3 ¬∑ 1,287 patients ¬∑ median 21 months follow-up</li>
          <li><strong>Enriched for high-bleeding-risk</strong>: prior GI bleed, prior ICH, age ‚â•80, CrCl 30‚Äì50, prior fall, frailty</li>
          <li>Comparator: rivaroxaban 20mg daily</li>
          <li>Abelacimab 150mg or 90mg SC monthly (blinded doses)</li>
          <li>Stopped early by IDMC ‚Äî overwhelming bleeding benefit</li>
        </ul>
      </div>
      <div class="card green-border">
        <div class="card-label green">Primary Results ‚Äî 150mg Dose</div>
        <ul>
          <li>Major/CRNM bleeding: <strong style="color:var(--green);">HR 0.38</strong> (95% CI 0.24‚Äì0.60) ‚Äî 62% RRR</li>
          <li>Major bleeding alone: <strong style="color:var(--green);">HR 0.33</strong> (95% CI 0.16‚Äì0.66) ‚Äî 67% RRR</li>
          <li>ARR: ~7.3%/year ¬∑ <strong style="color:var(--green);">NNT ~14</strong> over ~1.8 years</li>
          <li>ICH: <strong style="color:var(--green);">Near-eliminated</strong> in abelacimab arm</li>
          <li>Stroke/SE: Non-inferior to rivaroxaban (HR 1.11, 95% CI 0.58‚Äì2.14) ‚Äî <strong>underpowered</strong></li>
        </ul>
      </div>
    </div>
    <div class="sp12"></div>
    <div class="insight" style="font-size:clamp(12px,1.4vw,15px);">Ruff CT et al. ¬∑ NEJM 2025;392:361‚Äì371 ¬∑ TIMI Study Group ¬∑ NCT04755283</div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 17: LILAC NUMBERS ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-green" data-section="Trials">
    <div class="slide-label green">AZALEA-TIMI 71 ‚Äî Key Numbers</div>
    <h2>The Bleeding Reduction Is <em>Dramatic</em></h2>
    <div class="rule green"></div>
    <div class="sp24"></div>
    <div class="stat-row">
      <div class="stat-block">
        <div class="big green">67%</div>
        <div class="small">Relative reduction in major bleeding vs. rivaroxaban</div>
      </div>
      <div class="stat-block">
        <div class="big green">NNT 14</div>
        <div class="small">To prevent 1 major/CRNM bleed over ~1.8 years</div>
      </div>
      <div class="stat-block">
        <div class="big">HR 0.33</div>
        <div class="small">Major bleeding hazard ratio (95% CI 0.21‚Äì0.53)</div>
      </div>
      <div class="stat-block">
        <div class="big" style="color:var(--blue); font-size:32px;">~Zero</div>
        <div class="small">ICH events in abelacimab arm</div>
      </div>
    </div>
    <div class="sp32"></div>
    <div class="insight red" style="font-size:clamp(13px,1.6vw,18px);">
      <strong>The caveat:</strong> Trial was stopped early. Early stopping inflates point estimates ‚Äî a well-established statistical phenomenon. The NNT of 14 and HR of 0.33 are likely somewhat optimistic. Real-world data will show regression toward the mean.
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 18: LILAC CRITIQUE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-green" data-section="Trials">
    <div class="slide-label green">Critical Appraisal ‚Äî AZALEA-TIMI 71</div>
    <h2>Pressing the Findings</h2>
    <div class="rule green"></div>
    <div class="sp16"></div>
    <ul class="prompt-list">
      <li>Stopped early for <em>safety</em> benefit. Statistical consequence? How does the winner's curse affect interpretation of HR 0.33?</li>
      <li>Stroke/SE was non-inferior ‚Äî but the CI is wide (0.58‚Äì2.14) and only 25 total stroke events occurred. The trial was <em>not powered</em> for efficacy. What can and cannot we conclude? What trial would actually answer this?</li>
      <li>Population enriched for high-bleeding-risk. External validity to a general AF population? Would the NNT look the same in average-risk patients?</li>
      <li>Open-label design (SC vs. oral). Rivaroxaban patients knew their drug. Any ascertainment bias for bleeding endpoints?</li>
      <li>Monthly SC injection vs. daily oral. Will real-world adherence differences alter stroke prevention in ways the trial couldn't detect?</li>
    </ul>
  </div>


  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 18b: ACT IV ‚Äî LILAC-TIMI 76 ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-green" data-section="Trials">
    <div class="slide-label green">Act IV ¬∑ The Unanswered Question</div>
    <div class="act-marker" style="width:100%; max-width:700px;">
      <div class="act-line" style="background: rgba(34,197,94,0.3);"></div>
      <div class="act-label" style="color:var(--green);">LILAC-TIMI 76 ¬∑ Phase 3 ¬∑ Ongoing</div>
      <div class="act-line" style="background: rgba(34,197,94,0.3);"></div>
    </div>
    <div class="sp8"></div>
    <h2 class="green"><em>Abelacimab</em> vs. Placebo in AF</h2>
    <div class="rule green"></div>
    <div class="sp12"></div>
    <div class="cols cols-2" style="max-width:880px;">
      <div class="card">
        <div class="card-label green">What AZALEA Could Not Answer</div>
        <ul>
          <li>AZALEA proved bleeding reduction vs. rivaroxaban ‚Äî dramatic, consistent, credible</li>
          <li>AZALEA had only <strong>25 total stroke events</strong> ‚Äî cannot determine stroke efficacy</li>
          <li>Stroke/SE CI 0.58‚Äì2.14: abelacimab could double stroke risk vs. rivaroxaban and we couldn't detect it</li>
          <li>The core question: <em>does abelacimab actually prevent stroke?</em></li>
        </ul>
      </div>
      <div class="card green-border">
        <div class="card-label green">What LILAC-TIMI 76 Will Answer</div>
        <ul>
          <li>Phase 3 ¬∑ Event-driven ¬∑ Double-blind, placebo-controlled</li>
          <li>~1,900 patients deemed <strong>unsuitable for any anticoagulation</strong></li>
          <li>Primary endpoint: ischemic stroke or systemic embolism</li>
          <li>Abelacimab 150mg SC monthly vs. placebo</li>
          <li>Results expected: <strong>second half of 2026</strong></li>
        </ul>
      </div>
    </div>
    <div class="sp12"></div>
    <div class="insight red" style="font-size:clamp(12px,1.4vw,16px);">
      Until LILAC reports: AZALEA proves abelacimab is safer than rivaroxaban. It does not prove abelacimab prevents stroke. These are not the same statement.
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 19: REVERSAL ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-red" data-section="Reversal">
    <div class="slide-label red">‚ö† Critical Inpatient Gap</div>
    <h2>No Reversal Agents.<br><em>For Any Agent in This Class.</em></h2>
    <div class="rule red"></div>
    <div class="sp12"></div>
    <div class="reversal-alert">
      <div class="alert-title">What Does NOT Work ‚Äî Class-Wide</div>
      <ul>
        <li>Andexanet alfa ‚Äî designed for FXa inhibitors only, irrelevant here</li>
        <li>Idarucizumab ‚Äî dabigatran-specific, irrelevant here</li>
        <li>4F-PCC (Kcentra) ‚Äî not established; may not overcome mAb-mediated FXI inhibition</li>
        <li>FFP ‚Äî likely ineffective for abelacimab; possibly partial for small molecules</li>
        <li>rFVIIa (NovoSeven) ‚Äî theoretical bypass via extrinsic pathway; no clinical evidence</li>
        <li>Abelacimab t¬Ω = 30 days ‚Äî drug effect persists <strong>3+ months</strong> post-dose</li>
      </ul>
    </div>
    <div class="sp12"></div>
    <div class="insight red" style="font-size:clamp(13px,1.6vw,18px);">
      For life-threatening bleeding: supportive care + source control is primary. Consult hematology early. Management will be empirical. <strong>This must be weighed explicitly before prescribing.</strong>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 20: INPATIENT POPULATIONS ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Inpatient">
    <div class="slide-label">Hospital Medicine Implications</div>
    <h2>Which Patients Are We Talking About?</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <div class="cols cols-3" style="max-width: 980px;">
      <div class="card green-border">
        <div class="card-label green">Tier 1 ‚Äî Most Compelling</div>
        <ul>
          <li><strong style="color:var(--text);">AF + prior major GI bleed</strong> ‚Äî the AZALEA-TIMI 71 enrichment population; LILAC-TIMI 76 tests abelacimab vs. placebo in this group</li>
          <li><strong style="color:var(--text);">AF + prior ICH</strong> ‚Äî current standard is no anticoagulation; dramatic ICH reduction could be practice-changing</li>
          <li><strong style="color:var(--text);">AF + ESRD</strong> ‚Äî no renal clearance, no dose adjustment uncertainty</li>
        </ul>
      </div>
      <div class="card amber-border">
        <div class="card-label amber">Tier 2 ‚Äî High Interest</div>
        <ul>
          <li>AF + frailty / high fall risk</li>
          <li>AF + thrombocytopenia (oncology)</li>
          <li>VTE prophylaxis in high-risk surgical patients</li>
          <li>Patients who cannot tolerate oral medications</li>
        </ul>
      </div>
      <div class="card">
        <div class="card-label muted">Tier 3 ‚Äî Uncertain</div>
        <ul>
          <li>Mechanical heart valves ‚Äî likely contraindicated (no data)</li>
          <li>Antiphospholipid syndrome ‚Äî FXI not primary pathway</li>
          <li>Cancer-associated thrombosis ‚Äî awaiting trials</li>
          <li>AF + mild-moderate CKD ‚Äî DOAC options adequate</li>
        </ul>
      </div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 21: RETURN TO CASE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-amber" data-section="Inpatient">
    <div class="slide-label">Return to the Opening Case</div>
    <div class="sp8"></div>
    <div class="case-box">
      <div class="case-label">Reconsidering with AZALEA-TIMI 71 Data</div>
      <p>78F ¬∑ Paroxysmal AF ¬∑ CHA‚ÇÇDS‚ÇÇ-VASc 5 ¬∑ <strong>ESRD on HD</strong> ¬∑ <strong>GI bleed from cecal AVM, 4 months ago</strong> ¬∑ Apixaban on indefinite hold</p>
    </div>
    <div class="sp20"></div>
    <ul class="prompt-list">
      <li>Abelacimab reduced major bleeding by 67% vs. rivaroxaban in patients <em>exactly like her</em> ‚Äî prior GI bleed, ESRD, frailty. Does this change your decision?</li>
      <li>No renal clearance, no dose adjustment. Does the ESRD factor disappear?</li>
      <li>Monthly SC injection ‚Äî realistic in a dialysis patient with clinic access?</li>
      <li>She has no reversal option. Does that change your counseling? Your prescription?</li>
    </ul>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 22: DEBATE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Debate">
    <div class="slide-label">Structured Debate ‚Äî Split the Room</div>
    <h2>Motion: Adopt FXI Inhibitors as<br><em>First-Line</em> for High-Bleeding-Risk AF</h2>
    <div class="rule"></div>
    <div class="sp12"></div>
    <div class="debate-split">
      <div class="debate-col pro">
        <div class="dtitle">Argue For</div>
        <ul>
          <li>67% bleeding reduction ‚Äî no DOAC has achieved this</li>
          <li>ICH near-eliminated ‚Äî removes the most feared complication</li>
          <li>High-bleeding-risk patients currently get nothing ‚Äî any stroke reduction is a net gain</li>
          <li>No renal dosing complexity for abelacimab</li>
          <li>Monthly SC may improve adherence over daily pills</li>
          <li>Decades of FXI deficiency data support long-term safety concept</li>
        </ul>
      </div>
      <div class="debate-col con">
        <div class="dtitle">Argue Against</div>
        <ul>
          <li>OCEANIC-AF proves the class is not monolithic ‚Äî mechanism ‚â† guaranteed efficacy</li>
          <li>AZALEA-TIMI 71 underpowered for stroke efficacy ‚Äî we don't know if abelacimab matches apixaban vs. placebo (LILAC-TIMI 76, ongoing)</li>
          <li>No reversal: institutional risk management, trauma, urgent surgery</li>
          <li>Trial stopped early ‚Äî effect size likely inflated</li>
          <li>Cost, payer coverage, and injection infrastructure unknown</li>
          <li>No long-term (&gt;2 year) safety data at population scale</li>
        </ul>
      </div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 23: TAKEAWAYS ‚îÄ‚îÄ‚îÄ -->
  <div class="slide" data-section="Takeaways">
    <div class="slide-label">Six Things to Remember</div>
    <h2>Take-Home Points</h2>
    <div class="rule"></div>
    <div class="sp16"></div>
    <div class="takeaway-grid">
      <div class="takeaway-item"><div class="takeaway-n">01</div><div class="takeaway-t"><strong>The mechanism is real.</strong> Hemophilia C proves FXI inhibition reduces thrombosis with minimal spontaneous bleeding. The pharmacological rationale is sound.</div></div>
      <div class="takeaway-item"><div class="takeaway-n">02</div><div class="takeaway-t"><strong>FXI ‚â† FXIa.</strong> OCEANIC-AF's failure and AZALEA-TIMI 71's bleeding signal suggest complete upstream FXI blockade may be mechanistically superior to FXIa active-site competition ‚Äî but stroke efficacy awaits LILAC-TIMI 76.</div></div>
      <div class="takeaway-item"><div class="takeaway-n">03</div><div class="takeaway-t"><strong>AZALEA-TIMI 71's bleeding data is compelling ‚Äî Phase 3 must confirm.</strong> 67% RRR and near-zero ICH vs. rivaroxaban. LILAC-TIMI 76 (abelacimab vs. placebo, results 2026) is the definitive efficacy trial.</div></div>
      <div class="takeaway-item"><div class="takeaway-n">04</div><div class="takeaway-t"><strong>No reversal agents exist.</strong> Class-wide. Non-negotiable consideration for adoption. Abelacimab's 30-day half-life is the most acute problem.</div></div>
      <div class="takeaway-item"><div class="takeaway-n">05</div><div class="takeaway-t"><strong>Early stopping inflates effect size.</strong> NNT 14 and HR 0.33 are likely optimistic. Real-world data will show regression toward the mean.</div></div>
      <div class="takeaway-item"><div class="takeaway-n">06</div><div class="takeaway-t"><strong>Two trials to watch: LILAC-TIMI 76 and LIBREXIA-AF.</strong> LILAC (abelacimab vs. placebo, Ph3) answers stroke efficacy. LIBREXIA (milvexian, FXIa, Ph3) answers whether OCEANIC-AF failure was drug-specific or class-specific.</div></div>
    </div>
  </div>

  <!-- ‚îÄ‚îÄ‚îÄ SLIDE 24: CLOSE ‚îÄ‚îÄ‚îÄ -->
  <div class="slide bg-glow-amber" data-section="Close">
    <div class="slide-label">Questions & Discussion</div>
    <div class="sp8"></div>
    <h1>Thank you.</h1>
    <div class="title-rule"></div>
    <h3>Key evidence: AZALEA-TIMI 71 ¬∑ OCEANIC-AF ¬∑ Salomon et al. Blood 2008</h3>
    <div class="sp32"></div>
    <div class="meta-row">
      <div class="meta-item"><div class="meta-label">NEJM 2025</div><div class="meta-val">AZALEA-TIMI 71 ¬∑ Ruff CT et al.</div></div>
      <div class="meta-item"><div class="meta-label">NEJM/Circulation 2024</div><div class="meta-val">OCEANIC-AF Investigators</div></div>
      <div class="meta-item"><div class="meta-label">Circulation 2024</div><div class="meta-val">Weitz JI et al. ‚Äî FXI Review</div></div>
      <div class="meta-item"><div class="meta-label">Blood 2008</div><div class="meta-val">Salomon O et al. ‚Äî FXI Deficiency Data</div></div>
    </div>
    <div class="sp24"></div>
    <div class="insight" style="font-size:clamp(12px,1.4vw,16px); padding:16px 24px;">
      Full annotated reference document available at <strong>index.html</strong> in this repository ‚Äî detailed trial cards, presenter notes, and inpatient management guidance.
    </div>
  </div>

</div><!-- /deck -->

<!-- UI ELEMENTS -->
<div id="progress-bar" style="width:4.17%"></div>
<div id="slide-counter"><span id="cur">1</span> / <span id="tot">24</span></div>
<div class="section-pill" id="section-pill">Introduction</div>
<div id="nav-prev" class="nav-zone"><div class="nav-arrow">‚Äπ</div></div>
<div id="nav-next" class="nav-zone"><div class="nav-arrow">‚Ä∫</div></div>
<button id="fullscreen-btn">‚õ∂ Fullscreen</button>
<a href="moderator.html" style="position:fixed; top:48px; right:18px; z-index:100; background:rgba(167,139,250,0.08); border:1px solid rgba(167,139,250,0.2); border-radius:8px; padding:6px 12px; font-family:'JetBrains Mono',monospace; font-size:11px; color:rgba(167,139,250,0.6); text-decoration:none; letter-spacing:0.05em;">üìã Moderator</a>

<script>
  const slides = Array.from(document.querySelectorAll('.slide'));
  const total = slides.length;
  let current = 0;
  let animating = false;

  const progressBar = document.getElementById('progress-bar');
  const curEl = document.getElementById('cur');
  const totEl = document.getElementById('tot');
  const sectionPill = document.getElementById('section-pill');
  totEl.textContent = total;

  function goTo(index, dir) {
    if (animating || index === current || index < 0 || index >= total) return;
    animating = true;

    const prev = slides[current];
    const next = slides[index];

    // set exit direction
    if (dir > 0) prev.classList.add('exit-left');
    if (dir < 0) {
      prev.style.transform = 'translateX(60px)';
      prev.style.opacity = '0';
    }
    prev.classList.remove('active');

    // prepare incoming
    next.style.transform = dir > 0 ? 'translateX(60px)' : 'translateX(-60px)';
    next.style.opacity = '0';
    next.style.transition = 'none';
    next.classList.add('active');

    // force reflow
    next.getBoundingClientRect();

    next.style.transition = '';
    next.style.transform = 'translateX(0)';
    next.style.opacity = '1';

    current = index;

    // update progress
    const pct = ((current + 1) / total * 100).toFixed(2);
    progressBar.style.width = pct + '%';
    curEl.textContent = current + 1;
    sectionPill.textContent = slides[current].dataset.section || '';

    setTimeout(() => {
      prev.classList.remove('exit-left');
      prev.style.transform = '';
      prev.style.opacity = '';
      prev.style.transition = '';
      animating = false;
    }, 480);
  }

  function next() { goTo(current + 1, 1); }
  function prev() { goTo(current - 1, -1); }

  // Keyboard
  document.addEventListener('keydown', e => {
    if (e.key === 'ArrowRight' || e.key === 'ArrowDown' || e.key === ' ') { e.preventDefault(); next(); }
    if (e.key === 'ArrowLeft' || e.key === 'ArrowUp') { e.preventDefault(); prev(); }
    if (e.key === 'f' || e.key === 'F') toggleFullscreen();
  });

  // Touch swipe
  let touchStartX = 0, touchStartY = 0;
  document.addEventListener('touchstart', e => {
    touchStartX = e.touches[0].clientX;
    touchStartY = e.touches[0].clientY;
  }, { passive: true });

  document.addEventListener('touchend', e => {
    const dx = e.changedTouches[0].clientX - touchStartX;
    const dy = e.changedTouches[0].clientY - touchStartY;
    if (Math.abs(dx) > Math.abs(dy) && Math.abs(dx) > 40) {
      dx < 0 ? next() : prev();
    }
  }, { passive: true });

  // Nav zones
  document.getElementById('nav-next').addEventListener('click', next);
  document.getElementById('nav-prev').addEventListener('click', prev);

  // Fullscreen
  const fsBtn = document.getElementById('fullscreen-btn');
  function toggleFullscreen() {
    if (!document.fullscreenElement) {
      document.documentElement.requestFullscreen?.() ||
      document.documentElement.webkitRequestFullscreen?.();
      fsBtn.textContent = '‚úï Exit';
    } else {
      document.exitFullscreen?.() || document.webkitExitFullscreen?.();
      fsBtn.textContent = '‚õ∂ Fullscreen';
    }
  }
  fsBtn.addEventListener('click', toggleFullscreen);
  document.addEventListener('fullscreenchange', () => {
    if (!document.fullscreenElement) fsBtn.textContent = '‚õ∂ Fullscreen';
  });

  // ‚îÄ‚îÄ BroadcastChannel: sync with presenter.html ‚îÄ‚îÄ
  // Wrapped in try/catch ‚Äî navigation works standalone even if this fails
  try {
    const presenterChannel = new BroadcastChannel('fxi_slides');

    presenterChannel.postMessage({ type: 'SLIDES_READY' });

    // Respond to presenter.html reconnecting
    presenterChannel.addEventListener('message', e => {
      if (e.data.type === 'GOTO' && typeof e.data.index === 'number') {
        goTo(e.data.index, e.data.index > current ? 1 : -1);
        setTimeout(() => presenterChannel.postMessage({ type: 'SLIDE_CHANGED', index: current }), 50);
      }
      if (e.data.type === 'PRESENTER_READY') {
        presenterChannel.postMessage({ type: 'SLIDES_READY' });
      }
    });

    // Broadcast current slide after every local navigation
    const broadcastCurrent = () => {
      setTimeout(() => presenterChannel.postMessage({ type: 'SLIDE_CHANGED', index: current }), 50);
    };
    document.getElementById('nav-next').addEventListener('click', broadcastCurrent);
    document.getElementById('nav-prev').addEventListener('click', broadcastCurrent);
    document.addEventListener('keydown', e => {
      if (['ArrowRight','ArrowLeft','ArrowUp','ArrowDown',' '].includes(e.key)) broadcastCurrent();
    });
    document.addEventListener('touchend', broadcastCurrent, { passive: true });

  } catch(err) {
    // BroadcastChannel unavailable ‚Äî standalone mode, navigation unaffected
  }
</script>
</body>
</html>
